Relatlimab, an Immune Checkpoint Inhibitor that Blocks LAG-3, the Latest Drug to be Added to the Arsenal of Systemic Therapies for Melanoma: What Does a Surgical Oncologist Need to Know?

Ann Surg Oncol. 2024 Jan;31(1):1-3. doi: 10.1245/s10434-023-14416-0. Epub 2023 Oct 16.

Author

Alexander C J van Akkooi^{1

2

3}

Affiliations

¹ Melanoma Institute Australia, Sydney, NSW, Australia. alexander.vanakkooi@melanoma.org.au.
² Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia. alexander.vanakkooi@melanoma.org.au.
³ Department of Melanoma and Surgical Oncology, Royal Prince Alfred Hospital, Sydney, NSW, Australia. alexander.vanakkooi@melanoma.org.au.

PMID: 37843663
DOI: 10.1245/s10434-023-14416-0

No abstract available

Publication types

Editorial

MeSH terms

Antibodies, Monoclonal, Humanized
Humans
Immune Checkpoint Inhibitors / therapeutic use
Immunotherapy
Melanoma* / drug therapy
Melanoma* / surgery
Oncologists*

Substances

relatlimab
Immune Checkpoint Inhibitors
Antibodies, Monoclonal, Humanized